Skip to content

RIS International Cohort

The Radiologically Isolated Syndrome International Cohort

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05388331
Enrollment
1000
Registered
2022-05-24
Start date
2022-04-15
Completion date
2029-04-15
Last updated
2022-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Radiologically Isolated Syndrome

Brief summary

The Radiologically Isolated Syndrome (RIS) corresponds to the discovery of white matter (WM) abnormalities suggestive of multiple sclerosis (MS) by their location, size, and appearance, on the brain or spinal cord Magnetic Resonance Imaging (MRI). This imaging is performed for a reason other than for suspicion of demyelinating disease in subjects without a history of neurological symptoms and a strict routine clinical neurological examination. It was defined and named in 2009 (Okuda et al.) after publishing 3 case series (French, USA, Turkey). The Radiologically Isolated Syndrome Consortium (RISC) published a cohort of subjects with an extended follow-up after the first brain MRI of MS, with 34% presenting an event (clinical conversion) at five years, 51.2 % of these subjects showed an event at ten years. The patients who offer a higher risk of developing a first clinical demyelinating event were identified such as male sex, young age, the presence of oligoclonal bands (BOCs) in the Cerebrospinal Fluid (CSF), the presence of infratentorial lesions and spinal cord lesions on the first MRI suggestive of RIS. The location and morphology of the lesions appear to be decisive for studying the risk of conversion. Our first objective is to prospectively collect data to identify the subjects who present a higher risk of developing a first clinical demyelinating event and the progression of the disease in these subjects. Among the objectives of this worldwide cohort is the analysis of (1) environmental factors (Vit D, EBV, tobacco…), (2) MRI biomarkers, including atrophy, central veins signs, paramagnetic rings, and DTI. (3) digital biomarkers (4) oculography (5) biological markers To summarize, this cohort will allow for analyzing features in imaging, biology and the exploration of digital and oculographic characteristics to identify predictive factors of clinical evolution of a large cohort of subjects presenting WM abnormalities suggestive of multiple sclerosis.

Interventions

OTHERNo intervention

No intervention

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* white matter T2 lesions suggestive of demyelination * asymptomatic * normal neurological exam

Exclusion criteria

* abnormal neurological exam, * suspicion of another disease explaining MRI lesions.

Design outcomes

Primary

MeasureTime frameDescription
Identification of lesions T1 sequence with and without Gd at the index scan.at inclusionLesions number
Radiological progression : new contrast enhancing lesionsyear 1Lesions number
Brain atrophyyear 1measurement of global and regional grey matter volume measurement of global and regional white matter volume
Identification of lesions T2-weighted sequence at the index scanat inclusionnumber of T2-weighted sequence
Radiological progression : new T2 lesionsyear 1localisation of interest

Secondary

MeasureTime frameDescription
Collect digital markersat inclusionThe number of abnormalities identified by the eVOG application correlated with cerebral atrophy
Collect biological dataAt inclusionnumber of plasma samples

Countries

France

Contacts

Primary ContactChristine LEBNRUN-FRENAY
lebrun-frenay.c@chu-nice.fr33 4 92 03 41 26
Backup ContactCassandre LANDES
landes.c@chu-nice.fr33 4 92 03 41 26

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026